Skip to Content

Neoadjuvant nivolumab + chemotherapy improved pathological complete response rate regardless the stage of NSCLC

New analyses of CheckMate-816 how that neoadjuvant nivolumab in combination with platinum-doublet chemotherapy did not compromise tumor resection outcome and significantly improved pathological complete response rate compared to chemotherapy alone in patients with resectable non-small cell lung cancer.

Woman with cancer looking at x-ray

Få tilgang til artikkelen

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top